



(51) International Patent Classification:

C07D 487/04 (2006.01) C07D 401/04 (2006.01)
C07D 403/14 (2006.01) C07D 401/14 (2006.01)
C07D 403/04 (2006.01) A61K 31/519 (2006.01)
C07D 405/14 (2006.01) A61P 29/00 (2006.01)
C07D 405/04 (2006.01) A61P 35/00 (2006.01)
C07D 413/14 (2006.01)

(21) International Application Number:

PCT/CN2011/078575

(22) International Filing Date:

18 August 2011 (18.08.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201010257786.7 20 August 2010 (20.08.2010) CN
PCT/CN2010/076187
20 August 2010 (20.08.2010) CN

(71) Applicant (for all designated States except US):

HUTCHISON MEDIPHARMA LIMITED [CN/CN];
Building 4, 720 Cailun Road, ZJ. Hi-tech Park, Shanghai
201203 (CN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SU, Wei-Guo [US/
CN]; Building 4, 720 Cailun Road, ZJ. Hi-tech Park,
Shanghai 201203 (CN). DENG, Wei [CN/CN]; Building
4, 720 Cailun Road, ZJ. Hi-tech Park, Shanghai 201203
(CN). LI, Jinshui [CN/CN]; Building 4, 720 Cailun
Road, ZJ. Hi-tech Park, Shanghai 201203 (CN). JI, Jian-
guo [US/CN]; Building 4, 720 Cailun Road, ZJ. Hi-tech
Park, Shanghai 201203 (CN).


(74) Agent: ZHONGZI LAW OFFICE; 7F, New Era Build-
ing, 26 Pinganli Xidajie, Xicheng District, Beijing
100034 (CN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

[Continued on next page]

(54) Title: PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF



(57) Abstract: Disclosed are pyrrolopyrimidine compounds of formula (I) capable of inhibiting JAK kinase, wherein R¹, R² and m are defined as in the description. The pharmaceutical compositions containing said pyrrolopyrimidine compounds and uses of said pyrrolopyrimidine compounds in the treatment of disorders or diseases such as inflammatory diseases and cancers are also disclosed.



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*